

HUSKY Health Program Gene-Based Therapy for DMD Prior Authorization Request Form Phone: 1.800.440.5071

THIS FORM IS TO BE COMPLETED BY THE ORDERING PROVIDER AND FAXED WITH CLINICAL DOCUMENTATION TO 203.265.3994.

Member Information									
Member ID #:			Member Name (Last, First):						
DOB: Sex:		Sex:	Address:		City, State Zip:				
Diagnosis Code:		HCPCS Code:		Start Date of Service:					
Please fill out completely for all initial and reauthorization requests.									
1.	1. Treatment being requested:								
	a. Exon-Skipping Gene Therapy: Eteplirsen Golodirsen Viltolarsen Casimersen								
	b. Micro-Dystrophin Gene Therapy: Delandistrogene moxeparvovec-rokl								
2.	Type of request: □ Initial □ Reauthorization								
	Note: reauthorization requests for delandistrogene moxeparvovec-rokl are not considered medically necessary.						у.		
3.			pecialize in the treatm ysician who specialize		ne muscular dystrophy (DMD), or nent of DMD?	□ Yes	□ No		
4.	Will the physician follow all FDA recommendations for dosing, administration, and monitoring?				□ Yes	□ No			
Please fill out completely for Exon-Skipping Gene Therapy requests ONLY:									
1.					le to exon 51 skipping, confirmed	□ Yes	🗆 No		
	by genetic testing? If yes, please attach results of genetic testing.								
2.	Does the patien	t have a diagn	osis of DMD with mut	ation amenab	le to exon 53 skipping, confirmed	□ Yes	□ No		
	by genetic testing? If yes, please attach results of genetic testing.								
3.	Does the patient have a diagnosis of DMD with mutation amenable to exon 45 skipping, confirmed by genetic testing? <i>If yes, please attach results of genetic testing.</i>					□ Yes	□ No		
4.						□ No			
5.						□ Yes			
0.	performed? If yes, please attach results.								
6.	6. For <i>reauthorization</i> requests only: Does treatment with exon-skipping therapy continue to be medically necessary? <i>Please attach signed letter from ordering physician outlining benefits of</i> <i>treatment.</i>					□ Yes	□ No		
Place									
Please fill out completely for Micro-Dystrophin Gene Therapy requests ONLY: 1. Does the patient have a diagnosis of DMD with a mutation in the DMD gene, confirmed by genetic Section Section 1.									
			results of genetic te		Divid gene, commed by genetic				
2.	Does the patient have a deletion in exon 8 and/or exon 9 in the DMD gene? <i>Please attach results of genetic testing.</i>					□ Yes	□ No		
3.	Is the patient four years of age or older?				□ Yes	□ No			
4.	Does the patient have an elevated anti-AAVrh74 total binding antibody titer ≥ 1:400? <i>Please attach results of antibody titer.</i>					□ Yes	□ No		
5.	Has the patient previously received delandistrogene moxeparvovec-rokl?			□ Yes	□ No				
Billina	Billing Provider Information								
	id Billing Number			Billing Provid	der Name:				
Street Address:			City, State Zip:						
Contact Name:			Contact Telephone Number:						
Contact Fax Number:									



HUSKY Health Program Gene-Based Therapy for DMD Prior Authorization Request Form Phone: 1.800.440.5071

Ordering Provider Information					
Medicaid Billing Number:	Ordering Provider Name:				
Street Address:	City, State Zip:				
Contact Name:	Contact Telephone Number:				
Contact Fax Number:					
Certification Statement: This is to certify that the requested medication is medically indicated and is reasonable and necessary for the treatment of this patient, and that a prescribing practitioner-signed order is on file. This form and any statement on my letterhead attached hereto has been completed by me or by my employee and reviewed by me. The foregoing information is true, accurate, and complete, and I understand that any falsification, omission, or concealment of material fact may subject me to civil and criminal liability.					
Provider Signature:		Date:			